---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-065556"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-05-27T23:59:59+00:00"
generated_at: "2026-06-25T06:19:23.853820+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Hepion reports positive Phase 2a AMBITION NASH data; plans three Phase 2/2b trials starting Q3 2022

## Summary
- Phase 2a AMBITION NASH trial met primary endpoints: safety, tolerability, PK; no serious adverse events.
- Phase 2b ASCEND-NASH planned: 336 F2/F3 biopsy-proven NASH subjects, 12-month treatment, 3 doses vs placebo.
- Phase 2 ALTITUDE-NASH to assess liver function in 60 F3 NASH subjects using HepQuant SHUNT test, 4-month duration.
- Phase 2a HCC trial (Simon 2-stage) to enroll up to 42 advanced HCC subjects; primary endpoint disease control rate.
- Screening and enrollment for all three studies expected to begin in Q3 2022.

## SEC filing metadata
- accession: 0001104659-22-065556
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922065556/0001104659-22-065556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922065556/tm2217120d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-065556
- JSON: https://secwatch.observer/filing/0001104659-22-065556.json
- Plain text: https://secwatch.observer/filing/0001104659-22-065556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.